One, published in 2022, studying 250 women with breast cancer and 240 with ovarian cancer who underwent germline molecular testing for the detection of pathogenic BRCA1 and BRCA2 mutations, revealed that the most common variants identified were 5266delC, followed by 4218delG and c.68_69delAG for BRCA1, and c.9371A>T and c.1528G>T for BRCA2 [11]. This evidence concerns the gene BRCA2 and ovarian carcinoma.